Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

[Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].

Hou FQ, Yin YL, Zeng LY, Shang J, Gong GZ, Pan C, Zhang MX, Yin CB, Xie Q, Peng YZ, Chen SJ, Mao Q, Chen YP, Mao QG, Zhang DZ, Han T, Wang MR, Zhao W, Liu JJ, Han Y, Zhao LF, Luo GH, Zhang JM, Peng J, Tan DM, Li ZW, Tang H, Wang H, Zhang YX, Li J, Zhang LL, Chen L, Jia JD, Chen CW, Zhen Z, Li BS, Niu JQ, Meng QH, Yuan H, Sun YT, Li SC, Sheng JF, Cheng J, Sun L, Wang GQ.

Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):589-596. doi: 10.3760/cma.j.issn.1007-3418.2017.08.007. Chinese.

PMID:
29056008
2.

Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.

Luo X, Yu JX, Xie L, Ma WJ, Wang LH.

Ann Hepatol. 2017 November-December,;16(6):888-892. doi: 10.5604/01.3001.0010.5279.

3.

[Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].

Feng B, Shang J, Wu SH, Chen H, Han Y, Li YQ, Zhang DZ, Zhao LF, Wei SF, Mao Q, Yin CB, Han T, Wang MR, Chen SJ, Li J, Xie Q, Zhen Z, Gao ZL, Zhang YX, Gong GZ, Yang DL, Pan C, Sheng JF, Tang H, Ning Q, Shi GF, Niu JQ, Luo GH, Sun YT, You H, Wang GQ, Zhang LL, Peng J, Zhang Q, Liu JJ, Chen CW, Chen XY, Zhao W, Wang RH, Sun L, Wei L.

Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):187-194. doi: 10.3760/cma.j.issn.1007-3418.2017.03.006. Chinese.

PMID:
28482405
4.

[Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].

Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.

Zhonghua Gan Zang Bing Za Zhi. 2015 Nov;23(11):826-31. doi: 10.3760/cma.j.issn.1007-3418.2015.11.006. Chinese.

PMID:
26743242
5.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

6.

[Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].

Luo XD, Chen XP, Chen XF.

Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):896-901. doi: 10.3760/cma.j.issn.1007-3418.2017.12.003. Chinese.

PMID:
29325289
7.

[Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].

Luo XD, Chen XP, Chen R, Chen XF, Huang J.

Zhonghua Gan Zang Bing Za Zhi. 2016 Apr;24(4):241-5. doi: 10.3760/cma.j.issn.1007-3418.2016.04.001. Chinese.

PMID:
27470620
8.

[Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].

Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Oct;20(10):737-41. doi: 10.3760/cma.j.issn.1007-3418.2012.10.006. Chinese.

PMID:
23207332
10.
11.

[Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].

Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):335-9. doi: 10.3760/cma.j.issn.1007-3418.2013.05.006. Chinese.

PMID:
24025132
12.

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.

Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.

PLoS One. 2015 Apr 2;10(4):e0122259. doi: 10.1371/journal.pone.0122259. eCollection 2015.

13.

[Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].

Luo XD, Chen XP, Chen XF.

Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):583-588. doi: 10.3760/cma.j.issn.1007-3418.2017.08.006. Chinese.

PMID:
29056007
14.

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.

Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F; ANRS HB06 PEGAN Study Group.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188. doi: 10.1016/S2468-1253(16)30189-3. Epub 2017 Jan 20.

PMID:
28404133
15.

[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].

Yue W, Yuan H, Mao XR, Deng YD, Chen L.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8. Chinese.

PMID:
23967738
16.

Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.

Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.

J Clin Virol. 2013 Dec;58(4):713-7. doi: 10.1016/j.jcv.2013.09.020. Epub 2013 Sep 29.

PMID:
24183313
17.

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.

Dogan UB, Golge N, Akin MS.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1312-6. doi: 10.1097/MEG.0b013e328362389a.

PMID:
23652913
18.

Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.

Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1165-9. doi: 10.1097/MEG.0b013e3283612e95.

PMID:
23571612
19.

An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study.

Chon YE, Kim DJ, Kim SG, Kim IH, Bae SH, Hwang SG, Heo J, Jang JW, Lee BS, Kim HJ, Jun DW, Kim KM, Chung WJ, Choi MS, Jang JY, Yim HJ, Tak WY, Yoon KT, Park JY, Han KH, Suk KT, Lee HW, Jang BK, Ahn SH.

Medicine (Baltimore). 2016 Apr;95(14):e3026. doi: 10.1097/MD.0000000000003026.

20.

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.

Sun J, Ding H, Chen G, Wang G, Wei L, Zhang J, Xie Q, Wan M, Tang H, Chen S, Gao Z, Wang Y, Zhang D, Huang W, Sheng J, Ning Q, Yang D, Lu J, Pan C, Yang Y, Wang J, Sun C, Wang Q, Hou J.

BMC Gastroenterol. 2019 May 2;19(1):65. doi: 10.1186/s12876-019-0981-5.

Supplemental Content

Support Center